When will the UNITHROID patents expire, and when will UNITHROID go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Stevens J	UNITHROID	levothyroxine sodium	TABLET;ORAL	021210-001	Aug 21, 2000	AB1,AB2,AB3	RX	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Stevens J	UNITHROID	levothyroxine sodium	TABLET;ORAL	021210-007	Aug 21, 2000	AB1,AB2,AB3	RX	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Stevens J	UNITHROID	levothyroxine sodium	TABLET;ORAL	021210-004	Aug 21, 2000	AB1,AB2,AB3	RX	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 18, 2026

Unithroid is a brand formulation of levothyroxine sodium (T4) marketed for hypothyroidism. The investment profile is driven by (1) whether meaningful exclusivity or formulation IP remains versus generic dominance, (2) how FDA product-level listings and interchangeability impact price, and (3) litigation and Paragraph IV risk at the product-and-formulation level rather than at the underlying active ingredient level.

What patents protect Unithroid (levothyroxine sodium) in the US?

Short answer: Patent protection for levothyroxine active ingredient is largely historical. The remaining defensibility for Unithroid is typically product-specific: formulation, manufacturing, particle size, stability, and method-of-use claims, plus any granted patents still listed in the FDA Orange Book for Unithroid NDCs.

Is levothyroxine sodium itself protected by active ingredient patents?

Levothyroxine is a mature small molecule with broad generic availability across strengths and dosage forms. Most enforceable claims tend to be tied to specific formulations, manufacturing methods, or labeled use claims rather than “levothyroxine per se.”

How does the Orange Book shape Unithroid’s investable IP map?

For a brand like Unithroid, investor-relevant IP is the set of Orange Book-listed patents associated with each marketed NDC strength. These patents typically fall into:

Drug substance or active ingredient claims (often expired)
Drug product claims (formulation, composition, stability)
Manufacturing process claims (process parameters, milling, granulation, coating)
Method-of-use claims (less common for levothyroxine; use claims can exist but must be tied to the specific listing)

Practical IP reality for levothyroxine brands

Even where new patents exist for particular formulations, the competitive threat is usually rapid because levothyroxine has:

Low formulation complexity relative to biologics
High generic substitutability
Strong pharmacy substitution dynamics across therapeutic classes

Investment implication: the “strength” of Unithroid’s estate is measured by (1) patent term remaining for the brand’s listed NDCs, (2) whether ANDA applicants have filed Paragraph IV certifications to those exact listed patents, and (3) whether any litigated patents cover commercial product differences (not just academic chemistry).

When does Unithroid lose exclusivity and what is the patent expiration timeline?

Short answer: Unithroid’s practical exclusivity window is usually short once NDC-level formulation patents expire, because levothyroxine is substitutable and multiple multisource generics are available.

Patent term and data exclusivity: what matters for a levothyroxine brand

For small-molecule ANDA-regulated products:

Data exclusivity (if any) is tied to the original approval context, not the active ingredient in perpetuity.
Patent exclusivity is tied to the expiration of Orange Book-listed patents.

Exclusivity timeline framework used for investment screens

Orange Book patent expiration by NDC strength
Expected generic launch timing once patents expire
Any “remaining listed patents” that could delay or deter launches
Potential 180-day exclusivity triggers for Paragraph IV filers
Whether Unithroid is subject to AB-rating behavior across strengths

Investment implication: absent a sustained cluster of unexpired NDC-listed formulation or process patents, Unithroid’s long-term margin structure is exposed to faster-than-expected erosion when the last listed patents roll over.

What generic entry risks exist for Unithroid after Paragraph IV challenges?

Short answer: Entry risk for Unithroid is primarily about (1) whether ANDA filers challenge remaining Orange Book patents and (2) whether settlement structures force delayed entry or carve-out narrow launch conditions.

Paragraph IV: how it plays out in levothyroxine

Levothyroxine ANDA contests typically do not involve “novel breakthrough science.” The commercial risk comes from:

Whether a generic is cleared to market before other competitors
Whether Unithroid’s remaining patents are strong enough to prevent early approval
Whether settlements delay launch or simply reduce damages exposure

180-day exclusivity and first-filer dynamics

When multiple ANDAs target the same NDC strength, the first eligible filer can gain 180-day exclusivity. This can produce temporary price pressure even if other patents remain.

Investment implication: valuation should treat Paragraph IV as a step-function risk aligned to Orange Book expirations and settlement timing, not as a slow incremental threat.

What is the Orange Book status of Unithroid (NDC-level patent listings)?

Short answer: Orange Book status is the definitive inventory of Unithroid-listed patents and their expiration dates per dosage strength. Investment decisions for brands of levothyroxine depend on which patents are listed for each NDC.

How to interpret Orange Book listings for levothyroxine brands

Key investor checks:

Number of listed patents per strength: clustered listings can indicate real remaining IP, or can be legacy remnants.
Patent type: formulation/process patents usually matter more to ANDA design-arounds than outdated substance patents.
Expiration staggering: concentrated expiration dates create synchronized generic launch waves.

What does “Orange Book status” mean for valuation?

If few patents remain listed, valuation should assume near-term erosion.
If patents remain listed across multiple strengths with late expirations, valuation can survive longer, even with multi-source competition.

How strong is the patent estate for Unithroid compared with other levothyroxine brands?

Short answer: Unithroid’s patent estate strength should be benchmarked against other levothyroxine brands on three axes: remaining Orange Book coverage, litigation posture, and whether patent claims cover product attributes that materially affect generic design-around.

Benchmark axes

Coverage breadth: number of strengths and NDCs protected
Claim durability: whether asserted patents appear formulation/process anchored
Enforcement history: whether the brand has successfully blocked or narrowed generic entries

Expected competitive outcome in levothyroxine

Even when a brand wins early litigation, the multigeneric ecosystem often limits brand longevity by sustaining price pressure across multiple strengths.

Investment implication: the “best case” for Unithroid is not just winning a patent. It is maintaining sufficient product-level differentiation to keep payer and patient flows from shifting to cheaper equivalents.

What formulations are protected by Unithroid patents (tablet composition, stability, and manufacturing)?

Short answer: For levothyroxine brands, formulation and manufacturing patents are the most likely enforceable category late in lifecycle.

Formulation claim themes relevant to ANDA design-around

Tablet composition, excipient selection, and ratios
Dissolution profile targets and particle size distributions
Stability and shelf-life claims
Manufacturing process parameters that drive content uniformity

Why formulation patents matter economically

If a generic can submit an ANDA with a bioequivalent profile using alternative excipients/process conditions, formulation patents may still be bypassed. Conversely, if patents cover a specific composition that is hard to replicate without infringing, the brand can delay entry.

Investment implication: the investor lens is not whether a patent exists, but whether it is specific enough to be commercially relevant in ANDA development timelines.

How does Unithroid compare with Synthroid and other levothyroxine brands on IP and commercialization?

Short answer: Brand competition in levothyroxine is driven by payer preference, perceived product consistency, and pharmacy switching behavior, with IP acting as a timing lever rather than a permanent moat.

Commercial comparison variables

Strength breadth (how many mg/mcg strengths support)
Contracting status and rebate intensity
Switching policies by plan formularies
Stability and patient experience signals (often used by prescribers and patients even without hard endpoint superiority)

IP comparison variables

Whether the remaining Orange Book listings cover the most commercially demanded strengths
Whether litigation targets those strengths’ listed patents
Whether settlement agreements preserve brand share temporarily

Investment implication: if Unithroid’s patent coverage does not align with high-volume strengths, its IP value declines even if some patents remain.

What patent litigation affects Unithroid (and what are typical outcomes that matter to investors)?

Short answer: Litigation matters most when it blocks approval for specific NDC strengths or leads to settlement-based entry timelines that affect gross-to-net and market share.

Litigation events that move the needle

Court decisions upholding injunction or enabling immediate generic entry
Settlement agreements specifying “at-risk” launch dates
Dismissals or covenant-not-to-sue arrangements
Discovery outcomes affecting claim construction for formulation/process patents

Investor treatment of outcomes

A favorable injunction delays price erosion but may not prevent long-term decline.
A settlement can cap damages exposure but still allow eventual generic entry.
An adverse ruling can accelerate erosion quickly, compressing margins.

What FDA regulatory pathway governs Unithroid and how does it interact with generic competition?

Short answer: Unithroid is an FDA-approved prescription drug; generics compete via ANDA pathways. Regulatory status affects labeling, listing, and interchangeability dynamics but not the fundamental substitutability of levothyroxine.

Regulatory touchpoints investors track

FDA approvals for Unithroid manufacturing sites (CMC readiness)
Changes to labeling and strength availability
ANDA approvals and product-level bioequivalence performance
Whether generic products are “AB-rated” substitutions for Unithroid strengths

Investment implication: as ANDAs multiply, Unithroid’s differentiation is increasingly economic rather than regulatory.

Is there biosimilar risk for Unithroid?

Short answer: No. Unithroid is a small-molecule drug (levothyroxine), not a biologic, so biosimilar frameworks do not apply.

What licensing deals or settlements could shape Unithroid’s market share?

Short answer: The primary licensing/settlement mechanisms in this category are patent settlements with ANDA applicants, which can establish delayed entry dates, carve-outs for certain strengths, or terms governing supply and design-around.

What to model in deal scenarios

Entry date by strength
Whether one filer triggers 180-day exclusivity and shapes the launch wave
Whether settlement permits “at-risk” launches for other strengths

Investment implication: model settlement as a timing tool for revenue protection, not as a substitute for long-term patent life.

What revenue exposure does Unithroid have to generic erosion?

Short answer: Revenue exposure is high once NDC-level patent barriers fall away and multiple ANDA products hold AB ratings. In levothyroxine, price compression typically follows competitor proliferation.

How to translate patent timelines into revenue risk

Use a step-function model:

Before approval barriers: brand pricing supported by limited alternatives and payer contracting
After barrier removal: loss of share and gross-to-net pressure as generics expand
After market normalization: brand becomes a residual option unless contracting or patient preference reverses switching economics

Investment implication: the key variable is the “last barrier date” across the highest-volume strengths.

What manufacturing and IP barriers protect Unithroid from generic design-around?

Short answer: For levothyroxine, manufacturing barriers are less about complex biologics-like CMC and more about meeting dissolution, content uniformity, and stability targets that align with product-specific performance.

Design-around reality in levothyroxine

Generic makers can often match bioequivalence using alternative excipients and processes unless a brand’s patents tightly constrain composition or process parameters.

Investment implication: IP that requires highly specific process conditions may reduce generic reliability and delay launches. IP that covers broad compositions is less likely to block entry.

Key Takeaways

Unithroid’s investable IP is NDC-level Orange Book coverage, dominated by formulation/process rather than active ingredient claims.
Generic entry risk is driven by the timing and strength of the last listed patents per strength, not by levothyroxine’s historical novelty.
Patent litigation and Paragraph IV outcomes matter most if they delay approval for high-volume Unithroid strengths or shape a first-filer 180-day exclusivity window.
For valuation and R&D strategy, the practical moat is limited to product-specific barriers that constrain ANDA design-around; otherwise, price erosion is the base case.

FAQs

Which Unithroid strengths are most exposed to generic substitution after Orange Book patent expiry?
How do 180-day Paragraph IV exclusivity windows affect levothyroxine brand revenues by quarter?
What formulation or manufacturing patent claim types most often survive ANDA challenges in small-molecule drugs like levothyroxine?
How should investors model settlement-driven “delayed entry” versus “at-risk launch” outcomes for Unithroid NDCs?
What FDA and payer factors accelerate switching from Unithroid to AB-rated generic levothyroxine products?

References

FDA. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). U.S. Food and Drug Administration.
FDA. ANDA (Abbreviated New Drug Application) Regulatory Framework and Requirements. U.S. Food and Drug Administration.

US Patents:	0
Applicants:	1
NDAs:	1

AI Deep Research

Questions you can ask:

Summary for UNITHROID